Pneumocystis carinii pneumonia. Review of 53 cases
- PMID: 3492144
- DOI: 10.1016/0002-9343(87)90380-9
Pneumocystis carinii pneumonia. Review of 53 cases
Abstract
Between 1976 and 1983, 53 cases of Pneumocystis carinii pneumonia were documented at the Mayo Clinic. Underlying diseases included leukemia in 15 patients, lymphoma in nine, nonhematologic malignancies in five, acquired immune deficiency syndrome in two, an various inflammatory diseases treated by corticosteroids in 16 patients. Cytotoxic drugs with corticosteroids were used in 68 percent of patients, whereas 23 percent received corticosteroids alone. Clinical features consisted of progressive dyspnea (74 percent), cough (55 percent), and fever (62 percent), with normal findings on examination (43 percent), or crackles (53 percent). Arterial oxygen tension and oxygen saturation were 48.6 +/- 12.8 mm Hg and 81.2 +/- 6.5 percent, respectively. Chest roentgenographs exhibited diffuse alveolar and interstitial infiltrates with predominantly perihilar distribution. The diagnostic rates for open lung biopsy and bronchoscopy were 97 percent and 62 percent, respectively. Clinical improvement and survival following appropriate therapy were noted in 22 patients (41.5 percent), whereas the remaining 31 patients died within four weeks of hospitalization. When survivors were compared with nonsurvivors, there was no difference in mean age, leukocyte counts, arterial oxygen tension, or duration of symptoms before treatment. A coexisting pulmonary infection was identified more frequently in nonsurvivors (51.6 percent) than in survivors (22.7 percent, p = 0.01). The mortality from P. carinii pneumonia alone was 47 percent, whereas 76 percent of those with coexisting infection died. Despite antibiotic therapy and potentially effective chemoprophylaxis, P. carinii pneumonia remains a significant and life-threatening complication of diseases or treatments associated with immune suppression.
Similar articles
-
Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study.Ann Intern Med. 1988 Aug 15;109(4):280-7. doi: 10.7326/0003-4819-109-4-280. Ann Intern Med. 1988. PMID: 3260759 Clinical Trial.
-
Treatment of Pneumocystis carinii pneumonia in patients with AIDS.Clin Pharm. 1988 Jul;7(7):514-27. Clin Pharm. 1988. PMID: 3138063
-
Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial.Ann Intern Med. 1986 Jul;105(1):37-44. doi: 10.7326/0003-4819-105-1-37. Ann Intern Med. 1986. PMID: 3521428 Clinical Trial.
-
Pneumocystis carinii pneumonia.Front Radiat Ther Oncol. 1985;19:74-81. doi: 10.1159/000429345. Front Radiat Ther Oncol. 1985. PMID: 3884451 Review. No abstract available.
-
Pneumocystis carinii pneumonitis.Chest. 1984 Jun;85(6):810-3. doi: 10.1378/chest.85.6.810. Chest. 1984. PMID: 6373171 Review. No abstract available.
Cited by
-
The Impact of SIV-Induced Immunodeficiency on SARS-CoV-2 Disease, Viral Dynamics, and Antiviral Immune Response in a Nonhuman Primate Model of Coinfection.Viruses. 2024 Jul 21;16(7):1173. doi: 10.3390/v16071173. Viruses. 2024. PMID: 39066335 Free PMC article.
-
Pneumocystis carinii pneumonia in HIV-negative patients with haematologic disease.Infection. 1997 Mar-Apr;25(2):78-81. doi: 10.1007/BF02113579. Infection. 1997. PMID: 9108180
-
Pneumocystis carinii glycoprotein A binds macrophage mannose receptors.Infect Immun. 1995 Mar;63(3):779-84. doi: 10.1128/iai.63.3.779-784.1995. Infect Immun. 1995. PMID: 7868247 Free PMC article.
-
The Impact of SIV-Induced Immunodeficiency on Clinical Manifestation, Immune Response, and Viral Dynamics in SARS-CoV-2 Coinfection.bioRxiv [Preprint]. 2023 Nov 16:2023.11.15.567132. doi: 10.1101/2023.11.15.567132. bioRxiv. 2023. Update in: Viruses. 2024 Jul 21;16(7):1173. doi: 10.3390/v16071173. PMID: 38014096 Free PMC article. Updated. Preprint.
-
Focal lung uptake of gallium-67 in patients with acquired immunodeficiency syndrome secondary to pneumocystis carinii pneumonia.Eur J Nucl Med. 1988;14(7-8):424-6. doi: 10.1007/BF00254399. Eur J Nucl Med. 1988. PMID: 3263273
MeSH terms
Substances
LinkOut - more resources
Full Text Sources